Tau and p-Tau blood biomarkers to predict outcomes after complicated mild traumatic brain injury
Official title: Analytical Validation of Tau and P-Tau as Acute and Subacute Prognostic Biomarkers for Complicated Mild TBI
Funded at Foundation for Applied Molecular Evolutn · NIH-11578679 · Data updated 2026-11-12
A research team is validating Tau and phosphorylated Tau as blood biomarkers to help predict which patients with complicated mild TBI will have poorer outcomes.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Foundation for Applied Molecular Evolutn NIH-funded |
| Lab location | 1 site (Alachua, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $476,291 |
| NIH project number | 7U01NS111680-05 |
| Project ID | NIH-11578679 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years or older with complicated mild TBI who are in the acute to subacute phase after injury and are targeted for biomarker-based prognostic testing.
✕Less likely to help
Patients without CNS injury or those not undergoing biomarker testing may not directly benefit.
What this research studies
This project will carefully validate Tau and p-Tau biomarkers in blood to see how well they indicate prognosis after complicated mild TBI in adults. Researchers will create gold standards and reference samples, test new assay platforms at two sites, and establish baseline levels in healthy controls for comparison. The work aims to clarify how these biomarkers could inform prognosis during the acute and subacute phases after injury, potentially guiding management and follow-up. Results could lead to more precise risk assessment for persistent symptoms and long-term complications.
Why it matters
Potential benefit: If successful, patients with complicated mild TBI could receive better-informed prognostic information to guide treatment and recovery planning.
How similar studies have gone: Analytical validation of biomarkers for neurological injury is an active area with promising but not yet definitive results for Tau/P-Tau.
Where this research is happening
-
Foundation for Applied Molecular Evolutn
Alachua, United States Active
Researchers
- Principal investigator: Wang, Kevin Ka Wang — Foundation for Applied Molecular Evolutn
- Study coordinator: Wang, Kevin Ka Wang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.